We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Key Factors Signal Infection Risk in Alcoholic Hepatitis

By LabMedica International staff writers
Posted on 17 Aug 2021
Print article
Image: Histopathology shows extensive liver cell damage resulting from alcoholic hepatitis (Photo courtesy of The Johns Hopkins University)
Image: Histopathology shows extensive liver cell damage resulting from alcoholic hepatitis (Photo courtesy of The Johns Hopkins University)
Alcohol-associated hepatitis (AAH) is a severe form of liver injury with mortality as high as 30%-40% at 90 days. As a result of altered immune function in AAH, bacterial infections are common and are associated with poor outcomes.

Severe cases of AAH are characterized by new onset jaundice. Infections are common in severe AAH, with approximately 25% of patients presenting with community-acquired infection and a similar percentage found to develop nosocomial infections. The high rates of sepsis observed in AAH may be explained by the impact of alcohol excess on the immune system.

Gastroenterologists and their colleagues at the Mayo Clinic Rochester (Rochester, MN, USA) performed a retrospective study of consecutive patients admitted with a diagnosis of AAH at two independent tertiary centers from 1998 to 2018 (test cohort, n = 286) who developed infections following hospitalization. The cohort was 66% men, and the median age was 48 (range: 21-83) years. Corticosteroids were used in 32% of all patients with AAH.

Patients were diagnosed with AAH based on the clinical criteria and laboratory data including aspartate aminotransferase (AST) >50, aspartate aminotransferase/alanine aminotransferase (ALT) ratio >1.5, AST/ALT <400 IU/L, and serum bilirubin (total) >3.0 mg/dL. When the diagnosis of AAH remained unclear, a liver biopsy was obtained for confirmation. Types of infection were categorized as a urinary tract infection (UTI), bloodstream infection (BSI), pneumonia (PNA), spontaneous bacterial peritonitis (SBP), and Clostridium difficile (C. diff).

The scientists reported that the overall incidence of infection in the cohort was 36% (n = 102). They then excluded those who presented to the hospital with community-acquired infection, which was 12% (n = 34) of patients. The most common sources of infection at presentation were UTI (12), BSI (10), lower respiratory (6), SBP (3), and C. diff (3), and the most commonly identified organisms included Escherichia coli (8) and Staphylococcus aureus (6). Of those who developed an infection while hospitalized (31/286), the most common infection sources included lower respiratory tract infections (10), BSI (7), SBP (6), UTI (6), and C. diff (2).

Daniel Penrice, MD, a co-author of the study, said, “Our hope is that future studies can evaluate whether targeted prophylactic antibiotics for patients at high-risk for infection can improve survival. Our prediction model can likely be strengthened by the inclusion of novel biomarkers such as circulating serum bacterial DNA, endotoxin, or bacterial 16S ribosomal DNA.”

The authors concluded that in this multicenter cohort study of patients hospitalized with AAH, MELD score, ascites, WBC count, and use of corticosteroids were identified as significant predictors of the development of bacterial infection. They created a novel predictive equation that may be used to aid in the identification of patients with AAH at high risk of infection. The study was published on July 28, 2021 in the journal Hepatology Communications.

Related Links:
Mayo Clinic Rochester

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.